DAWN 250117 22.50P (DAWN250117P22500) Stock Options, News & Quotes

US OptionsDetailed Quotes

DAWN250117P22500

Watchlist

10.10
0.000.00%

15min DelayTrading Jun 10 12:58 ET

0.00High0.00Low

Intraday

5D
Daily

News

Day One Biopharm Is Maintained at Buy by Jones Trading
Dow JonesDec 17 12:28 ET · Ratings
Day One Biopharmaceutical Analyst Ratings
BenzingaDec 17 12:17 ET · Ratings
Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but With Extreme Concentration Risk
TipRanksDec 17 03:54 ET
JonesTrading Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Cuts Target Price to $34
Moomoo NewsDec 16 16:31 ET · Ratings
CBTN Partners With Day One to Drive New Therapies for Pediatric Brain Tumors
PR NewswireDec 16 09:56 ET
Piper Sandler Maintains Day One Biopharmaceuticals(DAWN.US) With Buy Rating, Maintains Target Price $40
Moomoo NewsDec 5 11:35 ET · Ratings

Comments

IDKWTFIMDOING

Jul 25 13:43

$Day One Biopharmaceuticals (DAWN.US)$
https://www.tipranks.com/news/blurbs/strong-buy-rating-for-day-one-biopharmaceuticals-amid-strategic-partnership-and-promising-financial-health?futusource=news_stock_stockpagenews&ns_stock_id=80620831336770&src=2&utm_medium=referral&utm_source=moomoo.com&client_hour_clock=24&clientlang=2

Trytosaveabit

Jul 25 02:47

$Day One Biopharmaceuticals (DAWN.US)$ Ipsen And Day One Enter Ex-U.S. Licensing Deal For Pediatric Brain Cancer Drug Tovorafenib
Benzinga· 01:54
Ipsen secures ex-U.S. regulatory and commercial rights to tovorafenib for most common childhood brain tumor, pediatric low-grade glioma (pLGG), and any future indications
OJEMDA (tovorafenib) is the first FDA-approved treatment for relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or V600 mutation, following the pivotal Phase II tria...

MARKET-TEST-DUMMY

Jun 19 15:39

turn around

$Day One Biopharmaceuticals (DAWN.US)$ we gonna see retraisement back to 18?

Trytosaveabit

Jun 12 06:34

Update

$XOMA Corp (XOMA.US)$ $Day One Biopharmaceuticals (DAWN.US)$ XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of Its Priority Review Voucher

Meltyy

May 16 01:19

🔔 RA Capital Q1 ‘24* Holdings Released... 🐳

» Holdings: 75
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$
...